Ann: Media clarification, page-46

Rat's Rant also picked it up today:

https://mailchi.mp/5d90a7ac4410/rats-rant-the-beginning-of-apple-edition?e=4d33d5ee4c

PAA - PharmAust Limited today closed up 13% to finish at 42.5c on $640k stock traded. There was no news out today but not long before the open they were placed in a trading halt pending an announcement in relation to an article in the West Australian.

The article in The West Australian included a quote from PharmAust CEO and long time reader of the Rant, Dr Michael Thurn that contained a targeted sales figure, which PAA has now retracted.Dr Thurn had said, “Based on the numbers of patients out there with MND, this drug could be a blockbuster. It could be a drug that makes more than $1 billion in sales.

”Naughty naughty Dr as I am sure you will read this tonight, jokes sometimes the journalists (real ones that is) just need a story but anyway hope it does come to fruition as got a few people that own some. PAA clarifies that this is not a forecast nor revenue projection, PharmAust is continuing development of the drug (monepantel) including the forthcoming global pivotal registration Phase 2/3 clinical study scheduled to start mid-2024.Any potential sales of the drug will be subject to these study outcomes, regulatory approval and various pharmaceutical reimbursement schemes.

The quote was provided based on the potential for sales of monepantel for the treatment of motor neurone disease (MND) / amyotrophic lateral sclerosis (ALS), should it be approved in major regulatory jurisdictions such as the US and Europe.In the US and western Europe, it is estimated there is more than 37,000 and 56,000 patients with MND/ALS, and more than 268,000 globally, the MND/ALS treatment market was valued at more than US$9 billion in 2022.You can find The West Australian article on the link below: